<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357939</url>
  </required_header>
  <id_info>
    <org_study_id>HLX03-HV01</org_study_id>
    <nct_id>NCT03357939</nct_id>
  </id_info>
  <brief_title>Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects</brief_title>
  <official_title>A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This healthy male volunteers study will evaluate 148 subjects who will receive a single&#xD;
      sub-cutaneous dose of HLX03 （a monoclonal antibody against TNF-a, 40 mg/ 0.8 mL） or&#xD;
      Adalimumab(Humira,China spourced,40 mg/0.8 mL injection with a single-use prefilled syringe).&#xD;
      This study will involve sampling,pharmacokinetics, safety, tolerability and immunogenicity&#xD;
      evaluation of drug levels following administration of HLX03 and the licensed adalimumab&#xD;
      products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, doubl-blinded, parellel-controlled phase 1 PK, safety, tolerability and&#xD;
      immunogenicitiy study to compare HLX03, designed as an Adalimumab biosimilar, with China&#xD;
      sourced Humira in Chinese health volunteers. All enrolled subjects will receive a single dose&#xD;
      of HLX03 (40 mg）or Humira(adalimumab, 40 mg) in subcutaneous injectioin after randomization.&#xD;
&#xD;
      The purpose of this study to prove the similarity in PK, Safety, tolerability and&#xD;
      immunogenicity beween HLX03（adalimumab biosimilar） and China sourced Humira and provide&#xD;
      evidence for Phase III comparison study.&#xD;
&#xD;
      The blood will be collected before drug administration, and at 1 hr、4 hr、8 hr、24 hr (1d)、48&#xD;
      hr (2d)、72 hr (3d)、96 hr (4d)、、144 hr (6d)、192 hr (8d)、240 hr (10d)、 336 hr (14d)、504 hr&#xD;
      (21d)、672 hr (28d)、840 hr (35d)、1008 hr (42d)、1176 hr (49d)、1344 hr (56d)、1680 hr (70d) after&#xD;
      drug injection for PK, ADA, etc analysis. All subjects also will be followed up at 0,&#xD;
      1,2,3,4,6,8,10,14,21,28,35, 42, 49, 56, and 70 days after drug administration for AE and&#xD;
      other specified outcomes.&#xD;
&#xD;
      The main endpoint is AUC from time zero to ∞. The second endpoints include Cmax, Tmax, T1/2,&#xD;
      CL, Vd and AUC（0-last）.&#xD;
&#xD;
      This is single center study in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2017</start_date>
  <completion_date type="Actual">September 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration（Cmax） of Adalimumab After Single SC Injection of HLX03/Humira</measure>
    <time_frame>71 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to the last quantifiable concentration</measure>
    <time_frame>71 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity</measure>
    <time_frame>71 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration（Tmax） of Adalimumab After Single SC Injection</measure>
    <time_frame>71 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time of adalimumab after single SC injection of HXL03/Humira</measure>
    <time_frame>71 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Immune System Disorder</condition>
  <arm_group>
    <arm_group_label>HLX03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX03</intervention_name>
    <description>A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.</description>
    <arm_group_label>HLX03</arm_group_label>
    <other_name>adalimumab biosimilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe</description>
    <arm_group_label>Humira</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Chinese males (age: 18~45 yrs) with contraception during and 3 months&#xD;
             post-dose. Healthy is defined as no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, full physical examination including blood pressure, pulse,&#xD;
             ECG, and laboratory testing.&#xD;
&#xD;
          2. BMI between 19.0 and 28.0 kg/m² and body weight between 55 kg and 80 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. suffering from active or latent tuberculosis or history of tuberculosis;&#xD;
&#xD;
          2. have heart disease or a history of heart disease;&#xD;
&#xD;
          3. suffer from mental illness or psychiatric history;&#xD;
&#xD;
          4. suffering from malignant tumors and their history;&#xD;
&#xD;
          5. suffering from herpes zoster and its history;&#xD;
&#xD;
          6. suffering from epilepsy and history of epilepsy;&#xD;
&#xD;
          7. be allergic to the drugs or its components with high sensitivity or allergic reaction,&#xD;
             detection of ADA (+);&#xD;
&#xD;
          8. patients who lost blood or donated more than 200 mL within the first 2 months before&#xD;
             the screening;&#xD;
&#xD;
          9. major surgery performed within 30 days prior to signing ICF;&#xD;
&#xD;
         10. live vaccine inoculation or vaccination within 12 weeks of screening, or possible&#xD;
             administration of vaccine during screening and study visits;&#xD;
&#xD;
         11. previous application of adalimumab or its biosimilars, or anti-TNF alpha drugs;&#xD;
&#xD;
         12. participating in other clinical trials within the first 3 months of the trial;&#xD;
&#xD;
         13. abnormal immune function within 4 weeks before screening;&#xD;
&#xD;
         14. the presence of invasive systemic fungal infection or other opportunistic infections&#xD;
             within 2 months prior to screening;&#xD;
&#xD;
         15. systemic or local infection, such as the risk of sepsis and / or known active&#xD;
             inflammation within 2 months before screening;&#xD;
&#xD;
         16. 2 months before the screening, there were severe infections in the hospital and / or&#xD;
             the need for intravenous antibiotics;&#xD;
&#xD;
         17. 4 or more upper respiratory tract infections occurred within 6 months prior to&#xD;
             randomization;&#xD;
&#xD;
         18. hepatitis B surface antigen (HBsAg) positive; if hepatitis B surface antigen (HBsAg)&#xD;
             negative, hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B&#xD;
             virus deoxyribonucleic acid (DNA) test &gt;0 IU/ml also ruled out;&#xD;
&#xD;
         19. hepatitis C virus (HCV) antibody positive;&#xD;
&#xD;
         20. human immunodeficiency virus (HIV) antibody positive;&#xD;
&#xD;
         21. Treponema pallidum (Treponema pallidum, TP) antibody positive;&#xD;
&#xD;
         22. anti nuclear antibody titer was 1:100 examination;&#xD;
&#xD;
         23. drug abusers, alcohol addicts;&#xD;
&#xD;
         24. , the researchers discretion of failure to follow the requirements of the program,&#xD;
             instructions and research limitations, such as uncooperative attitude, unable to&#xD;
             return to the Research Center for follow-up visits, or unable to complete the entire&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 1st affiliated hospital, Jilin University, PRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the 1st affiliated hospital of Jilin University</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 26, 2017</study_first_submitted>
  <study_first_submitted_qc>November 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLX03</keyword>
  <keyword>adalimumab</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>biosimilar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

